Foundayo (orforglipron) is a once-daily GLP-1 tablet. Treatment begins at the lowest strength and steps up gradually — here is what the first two stages involve, and why starting low matters.
What Foundayo is
Orforglipron, sold as Foundayo, is a GLP-1 receptor agonist taken as an ordinary tablet. It received a UK marketing authorisation from the MHRA on 10 August 2026 for weight management and type 2 diabetes — the first approval of this particular GLP-1 tablet in Europe.
It is worth being precise about what is new here, because the claim is often overstated. Orforglipron is not the first GLP-1 pill, and not the first oral GLP-1 — oral semaglutide came first, and the Wegovy Tablet we already prescribe is a GLP-1 you swallow. What is genuinely new is that orforglipron is the first small-molecule GLP-1 pill: it is not a peptide, so it survives digestion without the absorption enhancer peptide tablets rely on. That is why it can be taken at any time of day, with or without food or water, where the others require a fasting window.
Why treatment starts at 0.8mg
Every GLP-1 is introduced gradually, and Foundayo is no exception. The starting strength is 0.8mg once daily. This is not a therapeutic dose in itself — it exists to let the body adapt to the medicine before the strength increases.
The reason is tolerability. GLP-1 medicines slow the rate at which the stomach empties, and the side effects most people notice early on — nausea, reflux, changes to appetite and bowel habit — are largely a consequence of that. Introducing the medicine at a low strength and increasing in steps gives the gut time to adjust, and generally makes those effects milder and shorter-lived than they would be if treatment began higher.
Moving to 2.5mg
The second step is 2.5mg once daily. Most people move up after around four weeks at the starting strength, provided the first stage has been tolerated reasonably well.
That last part matters. Titration is not a fixed timetable to be pushed through — it is a decision made each cycle based on how you have actually got on. If side effects at 0.8mg were difficult, staying at the same strength for longer is a perfectly reasonable clinical choice, and often a better one than moving up and abandoning treatment altogether a fortnight later. Our prescribers review this at each reorder.
How to take it
- One tablet daily, swallowed whole.
- At any time of day — morning or evening, whichever you will remember.
- With or without food. No fasting window and no need to take it with water on an empty stomach.
- Try to take it at roughly the same time each day, to build the habit rather than for any pharmacological reason.
The absence of a fasting requirement is the practical difference most people notice compared with other oral GLP-1 options, and for some it is the deciding factor.
What to expect early on
Digestive side effects are the most common, and are usually at their most noticeable in the days following a step up in strength. Eating smaller portions, stopping when full rather than finishing what is in front of you, and going easy on rich or fatty food all tend to help. These effects typically settle as your body adjusts.
Weight change is gradual, and the early weeks are about establishing tolerance rather than results. In the Phase 3 ATTAIN-1 trial, participants on the 36mg dose lost on average 12.4% of their body weight over 72 weeks, alongside lifestyle counselling. Individual results vary, and that figure reflects a full course at a high strength — not the first month.
Is it right for you?
Foundayo is a prescription-only medicine, so whether it is appropriate depends on your BMI, your medical history, and what else you take. That is what the consultation is for. If you are already using a different GLP-1, you should not simply switch across on your own — dose equivalence between medicines is not straightforward, and a prescriber needs to confirm the right starting point.
If you are unsure whether a tablet or an injection suits you better, that is a reasonable thing to raise at consultation rather than decide in advance.
Availability at The Weight Clinic
We now prescribe and dispense Foundayo from our own GPhC-registered pharmacy. The 0.8mg and 2.5mg strengths are in stock and dispatch now — and because treatment starts at 0.8mg and moves up no faster than every 30 days, those are the two strengths almost everyone needs first.
The higher strengths — 5.5mg, 9mg, 14.5mg and 17.2mg — can be ordered today and ship from 29 September 2026. You'll see that date at checkout before you pay, and nothing is dispatched until the stock is with us.
Pricing is £115 a month for 0.8mg, 2.5mg and 5.5mg, £130 for 9mg, and £160 for 14.5mg and 17.2mg, plus £5 tracked delivery.
If you're already on another GLP-1
You can move across, but not at a matching dose — and this is the part most people expect to work differently from how it does. There is no conversion between these medicines. A patient on the highest strength of one product and a patient on a middling dose of another start orforglipron at the same place, because the milligram figures on the packs measure different molecules and aren't comparable.
So a switch begins at 0.8mg, the same as anyone starting fresh. Your prescriber will discuss timing with you — there's a short gap between your last dose of the old medicine and your first tablet, and some overlap in your system afterwards is expected rather than a problem.
One exception exists for people who have been on a maximum tolerated dose of an injectable for a long time and are maintaining rather than still losing. That's a clinical decision your prescriber makes at consultation, not something to select online.
